Galecto Biotech AB is a seed stage company founded by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform. The company develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Galecto is based in Copenhagen, Denmark.
Galecto, Inc. today announced the pricing of its initial public offering of 5,666,667 shares of common stock at a public offering price of $15.00 per share.2020/09/25
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials2020/05/19
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals
• Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies